Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised…

Overview of attention for article published in The Lancet, December 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 4 public wall posts from 3 users.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext?dgcid=raven_jbs_aip_email

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext?dgcid=raven_jbs_aip_email

抗病毒藥Molnupiravir無法降低COVID-19死亡或住院風險，但有助於加速康復《刺胳針》(The Lancet) 發表一項英國隨機對照試驗指出，Molnupiravir並不能降低已接種疫苗的高風險族群感染COVID-19後的住院或死亡風險，然而…

Failure of Molnupiravir to reduce Covid hospitalizations or deaths in a very large randomized trial (N>25,000 participants…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.